Lung cancer detection kit DR1116

apoptosisfor tumor markersserum

The presence of GRP in lung cancer samples was identified in 1983. In pathological situations, GRP has mitogenic activity in vitro in many tumors such as pancreatic, small cell lung (SCLC), prostate, kidney, breast and colorectal cancers.GRP could operate as an autocrine growth factor. In cancers, GRP induces cell growth and inhibits apoptosis by shutting down the endoplasmic reticulum stress pathway.The mechanisms of the impacted signal pathways have not been established.As early as 1994, research on Pro-GRP as a biomarker for small cell lung cancer began.Because of the very short half-life of GRP (2 minutes), the Pro-GRP is used for measurements and analysis. Since then, Pro-GRP has been used as a tumor marker for patients with small cell lung cancer (SCLC) in limited and extended stages. Product Description Commonly found in three types of human gastrin-releasing peptide precursor splice variants. Serum progastrin-releasing peptide has been shown to be a reliable marker for patients with small cell lung cancer (SCLC). Elecsys progastrin-releasing peptide assays for progastrin-releasing peptide in plasma and serum . Gastrin-releasing peptide precursor and nerve-specific enolase (NSE) are two molecules associated with neuroendocrine-derived tissues and tumors. Elevated levels of GRP are seen in a variety of tumors of neuroendocrine origin, including small cell lung cancer, carcinoid, undifferentiated large cell lung cancer with neuroendocrine function, medullary thyroid carcinoma, other neuroendocrine malignancies, and neuroendocrine malignancies. Endocrine function in androgen-independent prostate cancer subgroups.